These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27178984)

  • 1. Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer.
    Koinis F; Vetsika EK; Aggouraki D; Skalidaki E; Koutoulaki A; Gkioulmpasani M; Georgoulias V; Kotsakis A
    J Thorac Oncol; 2016 Aug; 11(8):1263-1272. PubMed ID: 27178984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
    Feng PH; Chen KY; Huang YC; Luo CS; Wu SM; Chen TT; Lee CN; Yeh CT; Chuang HC; Han CL; Lin CF; Lee WH; Kuo CH; Lee KY
    J Thorac Oncol; 2018 Jul; 13(7):958-967. PubMed ID: 29684573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
    Yang Z; Guo J; Cui K; Du Y; Zhao H; Zhu L; Weng L; Tang W; Guo J; Zhang T; Shi X; Zong H; Jin S; Ma W
    Biomed Pharmacother; 2020 Nov; 131():110740. PubMed ID: 32942159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
    Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
    Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
    Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
    Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDSC subtypes and CD39 expression on CD8
    Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
    Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
    J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating CD15
    Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
    Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
    Youn JI; Park SM; Park S; Kim G; Lee HJ; Son J; Hong MH; Ghaderpour A; Baik B; Islam J; Choi JW; Lee EY; Kim HR; Seo SU; Paik S; Yoon HI; Jung I; Xin CF; Jin HT; Cho BC; Seong SY; Ha SJ; Kim HR
    Sci Rep; 2020 Jun; 10(1):9050. PubMed ID: 32493990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients.
    Wang S; Fu Y; Ma K; Liu C; Jiao X; Du W; Zhang H; Wu X
    Clin Transl Oncol; 2014 Jul; 16(7):616-22. PubMed ID: 24193866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
    Adamo A; Frusteri C; Pilotto S; Caligola S; Belluomini L; Poffe O; Giacobazzi L; Dusi S; Musiu C; Hu Y; Wang T; Rizzini D; Vella A; Canè S; Sartori G; Insolda J; Sposito M; Incani UC; Carbone C; Piro G; Pettinella F; Qi F; Wang D; Sartoris S; De Sanctis F; Scapini P; Dusi S; Cassatella MA; Bria E; Milella M; Bronte V; Ugel S
    Oncoimmunology; 2023; 12(1):2253644. PubMed ID: 37720688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.